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Azithromycin in patients admitted to hospital with COVID-19 




Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory 
actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.
Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 
Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital 
with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were 
randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per 
day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment 
groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and 
were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and 
local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the 
outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat 
population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were 
eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 
65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly 
allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 
561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days 
(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 
10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days 
(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no 
significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation 
or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).
Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other 
prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted 
to patients in whom there is a clear antimicrobial indication.
Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research. 
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
A substantial proportion of individuals infected with 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) develop a respiratory illness requiring 
hospital care, which can progress to critical illness with 
hypoxic respiratory failure requiring prolonged ventilatory 
support. Among patients with COVID-19 admitted to 
UK hospitals in the first wave of the epidemic, the case 
fatality rate was greater than 26%, and in excess of 37% in 
patients requiring invasive mechanical ventilation.1
In patients with severe COVID-19, the host immune 
response is thought to play a key role in driving an acute 
pneumonic process with diffuse alveolar damage, 
inflammatory infiltrates, and microvascular thrombosis.2 
The beneficial effects of dexamethasone and other 
corticosteroids in patients with hypoxic lung damage 
suggest that other drugs that suppress or modulate the 
immune system might provide additional improvements 
in clinical outcomes.3,4
Macrolide antibiotics, such as azithromycin, clarith-
romycin, and erythromycin, are widely available and 
their safety is well established. In addition to antibacterial 
properties, they are known to have immunomodulatory 
activity, decreasing production of pro-inflammatory 
cytokines and inhibiting neutrophil activation.5–7 They are 
widely used both in bacterial pneumonia due to their 
antimicrobial activity and in chronic inflammatory lung 
disease due to their immunomodulatory effects.8–10 In 
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addition, azithromycin has in-vitro antiviral activity 
against a range of viruses and has been reported to 
inhibit SARS-CoV-2 replication in Vero cells and human 
epithelial cells at concentrations (50% effective concen-
tration 2·12 µM) that are achieved in lung tissue with a 
dose of 500 mg once per day.11–13
The use of macrolides in influenza-associated 
pneumonia has been associated with a faster reduction 
in inflammatory cytokines and, in combination with 
naproxen, decreased mortality.14–16 However, randomised 
trials have so far not shown convincing clinical benefit of 
macrolides in COVID-19.17–19 Here, we report the results of 
a randomised controlled trial of azithromycin in which we 
aimed to assess whether azithromycin improves clinical 
outcomes in patients admitted to hospital with COVID-19.
Methods
Study design and participants
The Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) trial is an investigator-initiated, individually 
randomised, controlled, open-label, adaptive platform 
trial to evaluate the effects of potential treatments in 
patients admitted to hospital with COVID-19. Details of 
the trial design and results for other possible treatments 
(dexamethasone, hydroxychloroquine, and lopinavir–
ritonavir) have been published previously.3,20,21 The trial is 
underway at 176 hospitals in the UK (appendix pp 2–22), 
supported by the National Institute for Health Research 
(NIHR) Clinical Research Network. The trial is 
coordinated by the Nuffield Department of Population 
Health at the University of Oxford (Oxford, UK), the 
trial sponsor. The trial is done in accordance with 
the principles of the International Conference on 
Harmonisation–Good Clinical Practice guidelines and 
approved by the UK Medicines and Healthcare products 
Regulatory Agency and the Cambridge East Research 
Ethics Committee (20/EE/0101). The protocol, statistical 
analysis plan, and additional information are available 
on the study website. Although the azithromycin, 
dexamethasone, hydroxychloroquine, lopinavir–ritonavir, 
convalescent plasma, and tocilizumab groups have now 
been stopped, the trial continues to study the effects of 
REGN-COV2 (a combination of two mono clonal anti-
bodies directed against SARS-CoV-2 spike glycoprotein), 
aspirin, and colchicine. Other treatments might be 
studied in future.
Patients admitted to hospital were eligible for the study 
if they had clinically suspected or laboratory confirmed 
SARS-CoV-2 infection and no medical history that might, 
in the opinion of the attending clinician, put the patient 
at substantial risk if they were to participate in the trial. 
Initially, recruitment was limited to patients aged at 
least 18 years, but from May 9, 2020, the age limit was 
removed. Patients with known prolonged QTc interval 
or hyper sensitivity to a macrolide antibiotic and those 
already receiving chloroquine or hydroxychloroquine 
were excluded from random assignment between 
azithromycin and usual care.
Written informed consent was obtained from all 
patients, or a legal representative if they were too unwell 
or unable to provide consent. 
Randomisation and masking
Baseline data were collected using a web-based case report 
form that included demographics, amount of respiratory 
support, major comorbidities, suitability of the study 
Research in context
Evidence before this study
Azithromycin is commonly used in patients with COVID-19 for 
either its antimicrobial, anti-inflammatory, or purported antiviral 
activity. We searched MEDLINE, Embase, bioRxiv, medRxiv, and 
the WHO International Clinical Trials Registry Platform, from 
Sept 1, 2019, up to Nov 12, 2020, for completed clinical trials 
published in any language evaluating the effect of azithromycin 
or other macrolide antibiotics in patients with COVID-19. 
We used the search terms (“COVID.mp.” OR “COVID-19.mp.” OR 
“SARS-CoV-2.mp.” OR “2019-nCoV.mp.” OR “coronavirus/” or 
“CORONAVIRUS.mp.”) AND (“azithromycin.mp.” OR “macrolide.
mp.”), filtered by randomised controlled trials according to 
validated filters. We identified three published randomised clinical 
trials (two at low risk of bias and one with some concerns due to 
limited information on the randomisation process) that 
compared the effect of azithromycin (500 mg once a day) to usual 
care in patients admitted to hospital with COVID-19. In all 
three studies, all patients also received hydroxychloroquine. 
None of the three studies, which in combination included 
1223 patients, found differences in mortality or odds of clinical 
improvement; however, all were underpowered to exclude 
moderate but clinically relevant treatment effects.
Added value of this study
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) 
trial is a large, randomised trial evaluating the effect of 
azithromycin monotherapy on mortality in patients admitted 
to hospital with COVID-19. We found no significant difference 
between the azithromycin group and the usual care group in 
28-day all-cause mortality, the probability of discharge alive 
within 28 days, or, among the patients who were not receiving 
invasive mechanical ventilation at randomisation, the 
probability of progressing to the composite outcome of 
invasive mechanical ventilation or death. We saw no evidence 
of clinical benefit of azithromycin in any patient subgroup.
Implications of all the available evidence
Azithromycin should not be used to treat patients admitted to 
hospital with COVID-19 unless there is a clear antimicrobial 
indication.
For the protocol, statistical 




www.thelancet.com   Vol 397   February 13, 2021 607
treatment for a particular patient, and treatment avail-
ability at the study site (appendix pp 23–25). Eligible and 
consenting patients were assigned to either usual standard 
of care or usual standard of care plus azithromycin or 
one of the other available RECOVERY treatment groups 
using web-based simple (unstratified) randomisation with 
allocation concealed until after randomisation (appendix 
pp 23–25). Randomisation to usual care was twice that of 
any of the active treatment groups the patient was eligible 
for (eg, 2:1 in favour of usual care if the patient was eligible 
for only one active group, 2:1:1 if the patient was eligible for 
two active groups). For some patients, azithromycin was 
unavailable at the hospital at the time of enrolment or a 
macrolide antibiotic was considered by the managing 
physician to be either definitely indicated or definitely 
contraindicated. These patients were excluded from the 
randomised comparison between azithromycin and usual 
care. Patients allocated to azithromycin were to receive 
azithromycin 500 mg by mouth, nasogastric tube, or 
intravenous injection once a day for 10 days or until 
discharge, if sooner. Allocated treatment was prescribed 
by the managing doctor. Azithromycin was supplied from 
routine National Health Service (NHS) stocks.
For eligible participants, factorial randomisations were 
introduced such that participants could simultaneously 
be randomly assigned to convalescent plasma versus 
REGN-COV2 versus usual care and to aspirin versus usual 
care (appendix pp 23–25). Within 21 days of initial random 
assignment, participants with evidence of hypoxia and 
inflammation could be additionally randomly assigned to 
tocilizumab versus usual care alone. Participants and local 
study staff were not masked to the allocated treatment. The 
steering committee, investigators, and all others involved 
in the trial were masked to the outcome data during the 
trial.
Procedures
A single online follow-up form was completed when 
participants were discharged from hospital, died, or at 
28 days after randomisation, whichever occurred earliest 
(appendix pp 29–35). Information was recorded on 
adherence to allocated study treatment, receipt of other 
COVID-19 treatments, duration of admission, receipt of 
respiratory or renal support, and vital status (including 
cause of death). In addition, routine health-care and 
registry data were obtained, including information on 
vital status (with date and cause of death), discharge 
from hospital, receipt of respiratory support, or renal 
replacement therapy. Details of how this information 
was used to derive baseline characteristics and clinical 
outcomes are provided in the appendix (pp 112–31).
Outcomes
Outcomes were assessed at 28 days after randomisation, 
with further analyses specified at 6 months. The primary 
outcome was 28-day all-cause mortality. Secondary 
outcomes were time to discharge from hospital and, 
among patients not on invasive mechanical ventilation at 
randomisation, invasive mechanical ventilation (including 
extracorporeal membrane oxygenation) or death. Pre-
specified subsidiary clinical outcomes were cause-specific 
mortality, use of haemodialysis or haemo filtration, major 
cardiac arrhythmia (recorded in a subset), and receipt 
and duration of ventilation. Among those on invasive 
mechanical ventilation at randomisation, a subsidiary 
clinical outcome of successful cessation of invasive 
mechanical ventilation was defined as cessation within 
(and survival to) 28 days. Information on suspected 
serious adverse reactions was collected in an expedited 
manner to comply with regulatory requirements.
Statistical analysis
An intention-to-treat comparison was made between 
patients randomly assigned to azithromycin and those 
Figure 1: Trial profile
*Number recruited overall during the period that participants could be recruited into the azithromycin comparison. 
†Some patients were included in both of the below groups. ‡2506 (97%) of those allocated to azithromycin and 
5054 (98%) of those allocated to usual care had a complete follow-up at time of analysis. §3993 patients were 
additionally randomly assigned to convalescent plasma versus REGN-COV2 versus control (1320 [51·1%] patients 
allocated to azithromycin versus 2673 [51·6%] patients allocated usual care) and 975 patients were additionally 
randomly assigned to aspirin versus usual care (323 [12·5%] patients allocated to azithromycin versus 
652 [12·6%] patients allocated usual care). ¶Includes 198 (7·7%) of 2582 patients in the azithromycin group and 
450 (8·7%) of 5181 patients in the usual care group allocated to tocilizumab. 
5181 allocated usual care alone
837 of 5054‡ received 
azithromycin or other macrolide§
893 proceeded to second
randomisation¶
9 withdrew consent
9433 randomised between azithromycin
and other RECOVERY groups
7763 randomised between azithromycin 
and usual care alone




16 442 patients recruited*
7009 excluded†
 3650 azithromycin unavailable
 4570 azithromycin considered unsuitable
2582 allocated azithromycin
2347 of 2506‡ received 
azithromycin or other macrolide§
375 proceeded to second 
randomisation¶
5181 included in 28-day 
intention-to-treat analysis
2582 included in 28-day 
intention-to-treat analysis
7 withdrew consent 
Articles
608 www.thelancet.com   Vol 397   February 13, 2021
randomly assigned to usual care but for whom 
azithromycin was both available and suitable as a 
treatment. For the primary outcome of 28-day mortality, 
the log-rank observed minus expected statistic and its 
variance were used to both test the null hypothesis of 
equal survival curves (ie, the log-rank test) and to calculate 
the one-step estimate of the mortality rate ratio. We 
constructed Kaplan-Meier survival curves to display 
cumulative mortality over the 28-day period. We used 
similar methods to analyse time to hospital discharge and 
successful cessation of invasive mechanical ventilation, 
with patients who died in hospital right-censored on 
day 29. Median time to discharge was derived from Kaplan-
Meier estimates. For the prespecified composite secondary 
outcome of invasive mechanical ventilation or death within 
28 days (among those not receiving invasive mechanical 
ventilation at randomisation) and the subsidiary clinical 
outcomes of receipt of ventilation and use of haemodialysis 
or haemofiltration, the precise dates were not available and 
so the risk ratio was estimated instead.
Prespecified analyses of the primary outcome were 
done separately in six subgroups defined by characteristics 
at the time of random assignment: age, sex, ethnicity, 
days since symptom onset, level of respiratory support, 
and use of corticosteroids (appendix p 105). Observed 
effects within subgroup categories were compared using 
a χ² test for heterogeneity or trend, in accordance with 
the prespecified analysis plan.
Estimates of rate and risk ratios are shown with 
95% CIs. All p values are two-sided and are shown 
without adjustment for multiple testing. The full 
database is held by the study team who collected the data 
from study sites and did the analyses at the Nuffield 
Department of Population Health (University of Oxford, 
Oxford, UK).
As stated in the protocol, appropriate sample sizes could 
not be estimated when the trial was being planned at the 
start of the COVID-19 pandemic as it was unknown 
how large the epidemic would become (appendix p 26). 
As the trial progressed, the trial steering committee, 
whose members were unaware of the results of the trial 
comparisons, determined that sufficient patients should 
be enrolled to provide at least 90% power at a two-sided 
p value of 0·01 to detect a clinically relevant proportional 
reduction in the primary outcome of 20% between the 
two groups. Consequently, on Nov 27, 2020, the steering 
committee, masked to the results, closed recruitment to 
Azithromycin (n=2582) Usual care (n=5181)
Age, years 65·4 (15·6) 65·2 (15·7)
<70* 1508 (58%) 3014 (58%)
≥70 to <80 615 (24%) 1167 (23%)
≥80 459 (18%) 1000 (19%)
Sex
Men 1604 (62%) 3215 (62%)
Women† 978 (38%) 1966 (38%)
Ethnicity
White 1961 (76%) 3978 (77%)
Black, Asian, and 
minority ethnic
372 (14%) 737 (14%)
Unknown 249 (10%) 466 (9%)
Number of days since 
symptom onset
8 (5–11) 8 (5–11)
Number of days since 
admission to hospital
2 (1–4) 2 (1–4)
Respiratory support received
No oxygen received 490 (19%) 918 (18%)
Oxygen only‡ 1940 (75%) 3963 (76%)
Invasive mechanical 
ventilation
152 (6%) 300 (6%)
Previous diseases
Diabetes 700 (27%) 1433 (28%)
Heart disease 693 (27%) 1350 (26%)
Chronic lung disease 621 (24%) 1313 (25%)
Tuberculosis 3 (<1%) 16 (<1%)
HIV 7 (<1%) 22 (<1%)
Severe liver disease§ 45 (2%) 65 (1%)
Severe kidney 
impairment¶
155 (6%) 334 (6%)
Any of the above 1507 (58%) 3013 (58%)
Use of corticosteroids
Yes 1567 (61%) 3171 (61%)
No 182 (7%) 397 (8%)
Not asked or 
missing||
833 (32%) 1613 (31%)
SARS-CoV-2 test result
Positive 2350 (91%) 4743 (92%)
Negative 202 (8%) 386 (7%) 
Unknown 30 (1%) 52 (1%)
Data are mean (SD), n (%), or median (IQR). SARS-CoV-2=severe acute respiratory 
syndrome coronavirus 2. *Includes 26 children (<18 years). †Includes 25 pregnant 
women. ‡Includes non-invasive ventilation. §Defined as requiring ongoing 
specialist care. ¶Defined as estimated glomerular filtration rate <30 mL/min per 
1·73 m². ||Information on use of corticosteroids was collected from June 18, 2020, 
onwards, following announcement of the results of the dexamethasone 
comparison from the RECOVERY trial. 
Table 1: Baseline characteristics





































Rate ratio 0·97 (0·87–1·07); log-rank p=0·50
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the azithromycin comparison as sufficient patients had 
been enrolled.
Analyses were done using SAS, version 9.4, and R, 
version 3.4.0. This trial is registered with ISRCTN, 
50189673, and ClinicalTrials.gov, NCT04381936.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between April 7 and Nov 27, 2020, 9433 (57%) of 
16 442 patients enrolled in the RECOVERY trial were 
eligible to be randomly allocated to azithromycin (ie, 
azithromycin was available in the hospital at the time 
and the attending clinician was of the opinion that the 
patient had no known indication for or contraindication 
to azithromycin, figure 1, appendix p 38). 2582 patients 
were randomly allocated to azithromycin and 5181 were 
randomly allocated to usual care, with the remainder being 
randomly allocated to one of the other treatment groups. 
The mean age of study participants in this comparison was 
65·3 years (SD 15·7) and the median time since symptom 
onset was 8 days (IQR 5–11; table 1; appendix p 38).
 The follow-up form was completed for 2506 (97%) 
patients in the azithromycin group and 5054 (98%) patients 
in the usual care group. Among patients with a completed 
follow-up form, 2269 (91%) allocated to azithromycin 
versus 68 (1%) allocated to usual care received at least 
one dose, and 2347 (94%) versus 837 (17%) received any 
macrolide antibiotic (appendix p 39). The median duration 
of treatment with azithromycin was 6 days (IQR 3–10). Use 
of other treatments for COVID-19 was similar among 
patients allocated azithromycin and among those allocated 
usual care, with more than half receiving a corticosteroid, 
about a quarter receiving remdesivir, about a fifth receiving 
convalescent plasma, and about a twelfth receiving 
tocilizumab or sarilumab (appendix p 39).
We observed no significant difference in the propor-
tion of patients who met the primary outcome of 
28-day mortality between the two randomised groups 
(561 [22%] of 2582 patients in the azithromycin group vs 
1162 [22%] of 5181 patients in the usual care group; 
rate ratio 0·97, 95% CI 0·87–1·07; p=0·50; figure 2). We 
observed similar results across all prespecified subgroups 
(figure 3). In an exploratory analysis restricted to the 
7093 (91%) of 7763 patients with a positive SARS-CoV-2 
test result, the result was similar (rate ratio 0·95, 95% CI 
0·86–1·06; p=0·38).
Figure 3: Effect of allocation to azithromycin on 28-day mortality by baseline characteristics
Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines 
through them correspond to 95% CIs. The ethnicity, days since onset, and use of corticosteroids subgroups exclude those with missing data, but these patients are 
included in the overall summary diamond. Information on use of corticosteroids was collected from June 18, 2020, onwards following announcement of the results 
of the dexamethasone comparison from the RECOVERY trial. *Includes patients receiving non-invasive ventilation. 
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Allocation to azithromycin was associated with a similar 
time until discharge from hospital alive as usual care 
(median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) and a 
similar probability of discharge alive within 28 days 
(69% vs 68%, rate ratio 1·04, 95% CI 0·98–1·10; p=0·19; 
table 2). Among those not on invasive mechanical 
ventilation at baseline, the number of patients progressing 
to the prespecified composite secondary outcome of 
invasive mechanical ventilation or death among those 
allocated to azithromycin was similar to that among those 
allocated to usual care (25% vs 26%, risk ratio 0·95, 
95% CI 0·87–1·03; p=0·24; table 2). Allowing for multiple 
testing in interpretation of the results, there was no 
evidence that the effect of allocation to azithromycin 
versus usual care on time until discharge from hospital 
alive or on invasive mechanical ventilation or death 
differed between pre specified subgroups of patients 
(appendix pp 43–44).
We found no significant differences in the prespecified 
subsidiary clinical outcomes of cause-specific mortality 
(appendix p 40), use of ventilation, successful cessation 
of invasive mechanical ventilation, or need for renal 
dialysis or haemofiltration (table 2). We observed no 
significant differences in the frequency of new cardiac 
arrhythmias (appendix p 41). There was one report of 
a serious adverse reaction believed to be related to 
azithromycin: a case of pseudomembranous colitis from 
which the patient recovered with standard treatment.
Discussion
The results of this large, randomised trial show that 
azithromycin is not an effective treatment for patients 
admitted to hospital with COVID-19. Allocation to 
azithromycin was not associated with reductions in 
mortality, duration of hospital stay, or the risk of being 
ventilated or dying for those not on ventilation at baseline. 
These results were consistent across the prespecified 
subgroups of age, sex, ethnicity, duration of symptoms 
before randomisation, level of respiratory support at 
randomisation, or use of corticosteroids at randomisation.
Azithromycin was proposed as a treatment for 
COVID-19 on the basis of its immunomodulatory 
activity.7 Although no major organisation or professional 
society has recommended the routine use of azithro-
mycin in COVID-19 unless there is evidence of bacterial 
superinfection, it has nevertheless been used widely in 
patients with COVID-19, particularly in combination 
with hydroxychloroquine.22–24 Macrolides have long been 
suggested as potential therapies for inflammatory viral 
pneumonias but this hypothesis has been based on 
in-vitro, animal, and observational data, with very little 
evidence of benefit in clinical trials.13–15 The benefit of 
dexamethasone in patients with COVID-19 requiring 
respiratory support suggests that inflammation has a 
causal role in mortality.3 Noting that the absence of 
meaningful effect of azithromycin was consistent 
regardless of whether patients were also being given a 
corticosteroid or not, we conclude that the immuno-
modulatory properties of azithromycin are either 
insufficient in COVID-19.
Macrolides are commonly used to treat bacterial 
infections of the lower respiratory tract because of their 
activity against Gram-positive bacteria and atypical 
pathogens such as Mycoplasma pneumoniae and Legionella 
spp, as well as their excellent tissue penetration. More 
than 75% of patients with COVID-19 who were admitted 
to hospital in the UK during 2020 were prescribed 
antibiotics and the widespread clinical use of macrolides 
in COVID-19 is likely to be driven largely by concerns 
of bacterial superinfection rather than purported 
immunomodulatory activity.25 It is therefore important 
to highlight that in patients with moderate or severe 
COVID-19, who might be expected to have some burden 
of secondary bacterial lung infection, there was no 
observed clinical benefit of azithromycin use. This 
absence of meaningful effect could either reflect the 
relatively low rate of secondary bacterial infection in 
COVID-19 or the widespread use of β-lactam or other 
antibiotics, which might have abrogated any antibacterial 
benefit of allocation to azithromycin in this trial.26,27 Our 
results showed that the addition of azithromycin to 
routine clinical care of patients admitted to hospital with 
COVID-19 confers no clinical benefit, whether that be 
anti-inflammatory or antimicrobial. Although we detected 
no harm to individual patients given azithromycin, there 





RR (95% CI) p value
Primary outcome
28-day mortality 561 (22%) 1162 (22%) 0·97 (0·87–1·07) 0·50
Secondary outcomes
Time to being discharged alive, 
days
10 (5 to >28) 11 (5 to >28) NA NA
Discharged from hospital within 
28 days
1788 (69%) 3525 (68%) 1·04 (0·98–1·10) 0·19
Receipt of invasive mechanical 
ventilation or death*
603/2430 (25%) 1273/4881 (26%) 0·95 (0·87–1·03) 0·24
Invasive mechanical ventilation 211/2430 (9%) 461/4881 (9%) 0·92 (0·79–1·07) 0·29
Death 496/2430 (20%) 1028/4881 (21%) 0·97 (0·88–1·07) 0·52
Subsidiary clinical outcomes
Receipt of ventilation† 226/1368 (17%) 491/2705 (18%) 0·91 (0·79–1·05) 0·20
Non-invasive ventilation 214/1368 (16%) 467/2705 (17%) 0·91 (0·78–1·05) 0·19
Invasive mechanical ventilation 57/1368 (4%) 115/2705 (4%) 0·98 (0·72–1·34) 0·90
Successful cessation of invasive 
mechanical ventilation‡
54/152 (36%) 96/300 (32%) 1·15 (0·82–1·62) 0·42
Use of haemodialysis or 
haemofiltration§
105/2539 (4%) 224/5102 (4%) 0·94 (0·75–1·18) 0·61
Data are n (%), median (IQR), or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day 
mortality, hospital discharge, and successful cessation of invasive mechanical ventilation, and risk ratio for other 
outcomes. NA=not applicable. *Analyses exclude those on invasive mechanical ventilation at randomisation. 
†Analyses exclude those on any form of ventilation at randomisation. ‡Analyses restricted to those on invasive 
mechanical ventilation at randomisation. §Analyses exclude those on haemodialysis or haemofiltration at 
randomisation. 
Table 2: Effect of allocation to azithromycin on key study outcomes
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antimicrobial agents. Azithromycin is classified within 
the WHO Watch Group of Antibiotics (ie, antibiotics that 
have higher resistance potential and should be prioritised 
as key targets of antimicrobial stewardship programmes).28 
In light of the new evidence from the RECOVERY trial, 
the widespread use of macrolides in particular and 
antibiotics in general in patients with COVID-19 should 
be questioned.29
Strengths of this trial included that it was randomised, 
had a large sample size, broad eligibility criteria, and 
more than 98% of patients were followed up for the 
primary outcome. The trial also had some limitations. 
Detailed information on laboratory markers of viral 
load, inflammatory status, immune response, coexistent 
bacterial infection, or use of non-macrolide antibiotics 
was not collected, nor was information on radiological or 
physiological outcomes. Following random assignment, 
17% of patients in the usual care group were given 
azithromycin or another macrolide antibiotic. Although 
this randomised trial is open label (ie, participants and 
local hospital staff are aware of the assigned treatment), 
the outcomes are unambiguous and were ascertained 
through linkage to routine health data systems (regardless 
of treatment allocation).
Three other randomised controlled trials have assessed 
the efficacy of azithromycin for the treatment of 
COVID-19 in patients admitted to hospital, all of which 
additionally treated patients with hydroxychloroquine.17–19 
The COALITION I and COALITION II trials found 
that for patients with COVID-19 who had been admitted 
to hospital, treatment with azithromycin and hydroxy-
chloroquine was not associated with any improvement 
in mortality, duration of hospital stay, or clinical status 
as assessed using an ordinal outcome scale.17,18 A small 
trial in Iran that randomly assigned patients to hydroxy-
chloroquine and lopinavir–ritonavir with or without 
azithromycin also found no significant difference in 
mortality or intensive care unit admission, but suggested 
a reduction in duration of hospital stay.19 The total 
number of patients in all three previous trials combined 
was 1223, with 130 deaths. The RECOVERY trial, with 
7763 participants and 1723 deaths in this assessment of 
azithromycin, is well powered to detect modest treatment 
benefits; however, none were observed.
At the time of writing, 24 trials evaluating the use of 
macrolides in patients with COVID-19 were registered in 
the WHO International Clinical Trials Registry Platform, 
of which three (COALITION I and COALITION II, and 
Q-PROTECT, a study in patients who had not been 
admitted to hospital) have published results.17,18,30 Of the 
remaining 21, 16 are studying macrolides in inpatients 
either alone or in combination with other putative 
treatments, while five are studying macrolides in patients 
who had not been admitted to hospital with suspected or 
confirmed COVID-19.
Although our findings do not address the use of 
macrolides for the treatment of patients with COVID-19 
who had not been admitted to hospital with early, mild 
disease, the results do show that azithromycin is not an 
effective treatment for patients admitted to hospital with 
COVID-19.
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